|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.780 HKD | +1.70% |
|
+5.52% | -22.65% |
| 06:53am | Sino Biopharmaceutical Plans HK$2 Billion Stock Buyback | MT |
| 30/05 | Sino Biopharmaceutical Limited Announces Approval For Marketing of Naldemedine For Opioid-Induced Constipation In Adults | CI |
| Fiscal Period: December | 2016 | 2017 (CNY) | 2018 (CNY) | 2019 (CNY) | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 2.69TCr | 2.88TCr | 2.62TCr | 2.89TCr | 3.18TCr | |||||
Total Revenues | 2.69TCr | 2.88TCr | 2.62TCr | 2.89TCr | 3.18TCr | |||||
Cost of Goods Sold, Total | 533.21Cr | 579.55Cr | 498.99Cr | 533.62Cr | 570.77Cr | |||||
Gross Profit | 2.15TCr | 2.3TCr | 2.12TCr | 2.35TCr | 2.61TCr | |||||
Selling General & Admin Expenses, Total | 1.27TCr | 1.26TCr | 1.11TCr | 1.22TCr | 1.31TCr | |||||
R&D Expenses | - | - | - | - | 586.62Cr | |||||
Other Operating Expenses | 415.57Cr | 454.02Cr | 470.37Cr | 556.92Cr | 83Cr | |||||
Other Operating Expenses, Total | 1.69TCr | 1.71TCr | 1.58TCr | 1.77TCr | 1.98TCr | |||||
Operating Income | 466.99Cr | 588.07Cr | 543.92Cr | 580.12Cr | 629.13Cr | |||||
Interest Expense, Total | -31Cr | -44Cr | -50Cr | -30Cr | -28Cr | |||||
Interest And Investment Income | 56Cr | 51Cr | 61Cr | 134.72Cr | 237.2Cr | |||||
Net Interest Expenses | 25Cr | 7.57Cr | 12Cr | 105.21Cr | 209.37Cr | |||||
Income (Loss) On Equity Invest. | 1.36TCr | -15Cr | -53Cr | -12Cr | -15Cr | |||||
Currency Exchange Gains (Loss) | - | 14Cr | -9.69Cr | -12Cr | 2.11Cr | |||||
Other Non Operating Income (Expenses) | 49Cr | 22Cr | 56Cr | 36Cr | 28Cr | |||||
EBT, Excl. Unusual Items | 1.9TCr | 616.35Cr | 549.74Cr | 697.1Cr | 853.17Cr | |||||
Impairment of Goodwill | -4.73Cr | - | - | -1.86Cr | - | |||||
Gain (Loss) On Sale Of Investments | 1.71Cr | -45Cr | -1.28Cr | -148.35Cr | -154.8Cr | |||||
Gain (Loss) On Sale Of Assets | 37.31L | 34.65L | 6.26Cr | 12Cr | 1.12Cr | |||||
Asset Writedown | -44Cr | -1.94Cr | - | -29Cr | -7.19Cr | |||||
Other Unusual Items | - | 8.01Cr | -14Cr | -2.08Cr | 2.04Cr | |||||
EBT, Incl. Unusual Items | 1.86TCr | 577.86Cr | 540.99Cr | 527.75Cr | 694.34Cr | |||||
Income Tax Expense | 195.79Cr | 78Cr | 80Cr | 49Cr | 162.89Cr | |||||
Earnings From Continuing Operations | 1.66TCr | 500.26Cr | 461.26Cr | 478.46Cr | 531.45Cr | |||||
Earnings Of Discontinued Operations | - | - | 48Cr | 158.01Cr | - | |||||
Net Income to Company | 1.66TCr | 500.26Cr | 509.74Cr | 636.47Cr | 531.45Cr | |||||
Minority Interest | -200.64Cr | -245.9Cr | -276.55Cr | -286.48Cr | -297.12Cr | |||||
Net Income - (IS) | 1.46TCr | 254.36Cr | 233.19Cr | 349.98Cr | 234.33Cr | |||||
Net Income to Common Incl Extra Items | 1.46TCr | 254.36Cr | 233.19Cr | 349.98Cr | 234.33Cr | |||||
Net Income to Common Excl. Extra Items | 1.46TCr | 254.36Cr | 184.72Cr | 191.97Cr | 234.33Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.78 | 0.14 | 0.13 | 0.19 | 0.13 | |||||
Basic EPS - Continuing Operations | 0.78 | 0.14 | 0.1 | 0.1 | 0.13 | |||||
Basic Weighted Average Shares Outstanding | 1.88TCr | 1.86TCr | 1.85TCr | 1.83TCr | 1.8TCr | |||||
Net EPS - Diluted | 0.73 | 0.12 | 0.13 | 0.19 | 0.13 | |||||
Diluted EPS - Continuing Operations | 0.73 | 0.12 | 0.1 | 0.1 | 0.13 | |||||
Diluted Weighted Average Shares Outstanding | 1.93TCr | 1.9TCr | 1.85TCr | 1.83TCr | 1.81TCr | |||||
Normalized Basic EPS | 0.53 | 0.07 | 0.04 | 0.08 | 0.13 | |||||
Normalized Diluted EPS | 0.51 | 0.07 | 0.04 | 0.08 | 0.13 | |||||
Dividend Per Share | 0.07 | 0.11 | 0.05 | 0.07 | 0.09 | |||||
Payout Ratio | 6.42 | 49.84 | 27.13 | 52.76 | 64.12 | |||||
American Depositary Receipts Ratio (ADR) | 20 | 20 | 20 | 20 | 20 | |||||
Supplemental Items | ||||||||||
EBITDA | 549.05Cr | 674.93Cr | 637.91Cr | 689.28Cr | 725.52Cr | |||||
EBITA | 469Cr | 590.3Cr | 547.83Cr | 583.01Cr | 630.9Cr | |||||
EBIT | 466.99Cr | 588.07Cr | 543.92Cr | 580.12Cr | 629.13Cr | |||||
EBITDAR | 561.98Cr | 687.03Cr | 651.9Cr | 716.32Cr | 758.85Cr | |||||
Effective Tax Rate - (Ratio) | 10.54 | 13.43 | 14.74 | 9.34 | 23.46 | |||||
Current Domestic Taxes | 74Cr | 78Cr | 61Cr | 98Cr | 175.09Cr | |||||
Total Current Taxes | 74Cr | 78Cr | 61Cr | 98Cr | 175.09Cr | |||||
Deferred Domestic Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | 121.72Cr | -17.06L | 19Cr | -49Cr | -12Cr | |||||
Normalized Net Income | 989.37Cr | 139.32Cr | 67Cr | 149.2Cr | 236.11Cr | |||||
Interest on Long-Term Debt | 13Cr | 9.96Cr | 3.02Cr | 78.73L | 44.02L | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 1.05TCr | 1.04TCr | 919.34Cr | 1.01TCr | 1.1TCr | |||||
General and Administrative Expenses | 205.59Cr | 208.37Cr | 173.34Cr | 208.15Cr | 214.35Cr | |||||
Research And Development Expense From Footnotes | 374.71Cr | 433.26Cr | 447.3Cr | 523.49Cr | 603.63Cr | |||||
Net Rental Expense, Total | 13Cr | 12Cr | 14Cr | 27Cr | 33Cr | |||||
Imputed Operating Lease Interest Expense | 2.41Cr | 3.22Cr | 4.13Cr | 5.69Cr | 5.76Cr | |||||
Imputed Operating Lease Depreciation | 11Cr | 8.88Cr | 9.86Cr | 21Cr | 28Cr | |||||
Stock-Based Comp., Other (Total) | - | 2.97Cr | 1.81Cr | 5.37Cr | 12Cr | |||||
Total Stock-Based Compensation | - | 2.97Cr | 1.81Cr | 5.37Cr | 12Cr |
- Stock Market
- Stocks
- 1177 Stock
- Financials Sino Biopharmaceutical Limited
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















